Bob Nelsen Lands No. 5 on Forbes Midas List After $9B Juno Therapeutics Exit; Seattle Largely Absent
Forbes’ Midas List names ARCH Venture Partners’ Bob Nelsen No. 5 after his early investment in Seattle-based Juno Therapeutics, which was acquired by Celgene for $9 billion, while few other Seattle investors made the top 100.